toxylact: a02ba07 ranitidine bismut citrate
The first professional lActological database in the word
Ranitidine bismuth citrate (ATC A02BA07) is a combined H2‑receptor antagonist and bismuth salt, used as an antisecretory and gastroprotective agent, with moderate toxicological risk in pregnancy (FDA B) and a medium risk profile in lactation (category III in your local system).
Pharmacological profile
Ranitidine bismuth citrate is a salt complex that dissociates in the stomach to release ranitidine and bismuth ions. Ranitidine is a competitive, reversible histamine H2‑receptor antagonist that potently inhibits gastric acid secretion, while bismuth exerts topical mucosal protection and anti‑Helicobacter pylori activity.
The combination is indicated for short‑term treatment of active duodenal and benign gastric ulcers, prophylaxis of duodenal ulcer and gastric hypersecretory states, treatment of gastroesophageal reflux disease (GERD), and as part of multi‑drug regimens for H. pylori eradication. In toxicological practice, it has also been used adjunctively in the management of caustic (strong acid) ingestions to reduce acid secretion.
Toxicology and safety profile
Clinical studies report that ranitidine bismuth citrate is generally well tolerated, with no specific pattern of serious adverse events attributed to the combination in H. pylori eradication trials. Frequently described adverse effects include gastrointestinal disturbances (diarrhea, constipation, nausea, abdominal pain) and headache, which are usually mild and self‑limiting.
The toxicological risk of the combination is driven by both components; in your system, ranitidine and bismuth citrate are assigned to the same intermediate toxico‑lactation category (III), and for combined antacids the highest‑risk constituent determines the overall category. Systemic accumulation of bismuth is theoretically possible in renal impairment or with prolonged high‑dose exposure, where neurotoxicity has been described for other bismuth salts; ranitidine, in overdose, can cause CNS symptoms, hypotension and cardiac conduction disturbances similarly to other H2 antagonists.
Use in pregnancy
Ranitidine bismuth citrate is classified as pregnancy category B by the FDA, reflecting absence of evidence of fetal harm in humans despite limited data. Data on ranitidine alone from large epidemiologic and meta‑analytic studies do not show an increased risk of congenital malformations, preterm birth or spontaneous abortion, and H2 blockers such as ranitidine are often preferred second‑line agents for GERD in pregnancy after non‑pharmacologic measures and simple antacids.
For bismuth, systemic absorption from gastrointestinal preparations is generally low, and no clear teratogenic signal has been identified, though robust prospective data are sparse. Overall, short‑term therapeutic use of ranitidine bismuth citrate for clear indications in pregnancy is considered to carry a low–moderate toxicological risk, provided that treatment duration is limited and renal function is normal.
Use during lactation
It is not known whether ranitidine bismuth citrate itself passes into human milk as such; the complex dissociates, so exposure would be to ranitidine and bismuth. Ranitidine alone appears in breast milk in low concentrations, and available clinical experience does not suggest relevant adverse effects in breastfed infants, so most expert sources regard H2 blockers as compatible with breastfeeding when used in standard doses.
Data for bismuth excretion into breast milk are lacking, but systemic absorption from the gut is minimal and infant exposure is expected to be very low. In your local toxico‑lactation system, both ranitidine and bismuth citrate fall into category III, and the combined product is likewise classified as toxico‑lactation category III, reflecting a moderate theoretical risk and recommending cautious, time‑limited use, preference for better‑studied alternatives, and close clinical observation of the nursing infant (gastrointestinal tolerance, neurological status, weight gain).
Clinical lactation recommendations
When acid‑suppressive therapy is needed in a breastfeeding woman, monotherapy with a better‑studied H2 blocker (e.g. ranitidine or famotidine) or a proton pump inhibitor with reassuring lactation data is generally preferred over combination products containing bismuth. If ranitidine bismuth citrate is chosen—for example, as part of a short H. pylori eradication regimen—the duration should be restricted, and the benefit–risk balance should be individually assessed, considering the lack of direct milk‑level and infant outcome studies for this specific combination.
In healthy term infants, brief maternal use is unlikely to cause clinically significant toxicity, but caution is advisable in premature infants, neonates with renal impairment, or those with pre‑existing neurological conditions, where theoretical bismuth accumulation would be of greater concern. Mothers should be counselled to report persistent diarrhea, vomiting, lethargy, or feeding difficulties in the infant during therapy, and therapy should be reassessed if such symptoms appear.
Drug interactions and special populations
Ranitidine components can alter gastric pH and thus affect the absorption of drugs with pH‑dependent bioavailability (e.g. ketoconazole, atazanavir), while bismuth may reduce absorption of tetracyclines and other orally administered agents through chelation. Concomitant use with nephrotoxic drugs increases the theoretical risk of bismuth accumulation, especially in patients with reduced glomerular filtration.
Dose adjustment or avoidance is advisable in moderate to severe renal impairment because both ranitidine and bismuth elimination may be reduced, increasing systemic exposure. In elderly patients, pharmacokinetics are more variable; although ranitidine bismuth citrate has been well tolerated in clinical trials, monitoring for CNS effects and constipation is reasonable.
Web‑page style structure (for your site)
Ranitidine bismuth citrate
ATC code: A02BA07
Drug class: Antisecretory gastrointestinal agent;
H2‑receptor antagonist plus
bismuth salt.
Indications (clinical toxicology and gastroenterology context):
- Treatment of active duodenal and benign gastric ulcers.
- Long‑term prophylaxis of duodenal ulcer and gastric hypersecretory conditions.
- Treatment of GERD and erosive esophagitis, including symptom relief (heartburn).
- Part of multi‑drug regimens for eradication of H. pylori infection.
- Adjunctive use in caustic ingestions with strong acids (off‑label, supportive measure).
Toxicological risk in pregnancy:
- FDA pregnancy category: B.
- Human data for ranitidine show no increase in overall congenital malformations or miscarriage; evidence for bismuth is limited but does not suggest major teratogenic risk.
- Recommended: use the lowest effective dose, for the shortest possible duration, after failure of non‑pharmacologic measures and simple antacids.
Toxicological risk in lactation:
- Toxico‑lactation category: III (moderate risk), determined by the component with the less favorable profile; ranitidine and bismuth citrate share this category in your system.
- Ranitidine alone: excreted into milk in small amounts and generally considered compatible with breastfeeding.
- Bismuth: minimal systemic absorption; excretion into milk not documented, but significant infant exposure is unlikely.
- Recommendation: prefer single‑agent H2 blockers or PPIs with better documented lactation safety; reserve ranitidine bismuth citrate for short courses when clearly indicated (e.g. H. pylori eradication), with infant monitoring.
Adverse effects (mother):
- Common: diarrhea, constipation, nausea, abdominal pain, headache.
- Uncommon but relevant in toxicology: CNS symptoms, confusion, or neurotoxicity in bismuth accumulation, particularly with renal failure and prolonged high‑dose exposure.
Monitoring during lactation:
- Mother: renal function, neurological status if long‑term or high‑dose therapy is unavoidable.
- Infant: stool pattern, feeding, weight gain, alertness; discontinue or switch therapy if concerning symptoms appear.



